The PRIME Care Trial shows benefits of using pharmacogenomics to treat mental health conditions. Take this course to learn how using this information can gain better outcomes in treating depression.

Upon successful completion of this application-based course, participants should be able to:
1. Describe how pharmacogenomics (PGx) testing can impact medications related to depression
2. Recognize the impact of a multigene PGx panel on remission and response rates in patients with depression.
3. Describe how PGx testing impacts rates of drug-gene interactions
4. Discuss the strengths, limitations, and results of the PRIME Care Trial
5. Develop a conclusion for the role of pharmacogenomics in patient-centered depression care based on a clinical trial

Jordan Baye, PharmD, MA, BCPS
Assistant Professor
South Dakota State University College of Pharmacy & Allied Health Professions

Dr. Baye has no relevant financial relationships with ineligible companies to disclose. 

To obtain 1 contact hour of continuing pharmacy education credit (0.1 CEU), participants must read the article cited below.

Oslin DW, Lynch KG, Shih M, et al. Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: The PRIME Care Randomized Clinical Trial. JAMA. 2022;328(2):151–161. doi:10.1001/jama.2022.9805

*CEimpact provides you with two (2) opportunities to complete the exam. If there are two failed attempts, the participant will not receive CPE credit.

This course is included in our Pharmacist Membership. To get more courses like this sent to you every month, sign-up!

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Initial Release Date: April 12, 2023
Planned Expiration Date: April 12, 2026 

Copyright 2023, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.  

RV1-1.24